Pharmaceutical policies in European countries in response to the global financial crisis.
about
A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and developmentComprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.Impact of pharmaceutical policy interventions on utilization of antipsychotic medicines in Finland and Portugal in times of economic recession: interrupted time series analyses.Effect of the economic recession on pharmaceutical policy and medicine sales in eight European countries.Prescribing efficiency of proton pump inhibitors in China: influence and future directionsImpact of changes to reimbursement of fixed combinations of inhaled corticosteroids and long-acting β₂ -agonists in obstructive lung diseases: a population-based, observational studyEffects of drug price reduction and prescribing restrictions on expenditures and utilisation of antihypertensive drugs in Korea.A review of pharmaceutical policies in response to economic crises and sanctionsEstimating the Fiscal Effects of Public Pharmaceutical Expenditure Reduction in Greece.Greek Physicians' Perceptions on Generic Drugs in the Era of AusterityCost-Sharing Rates Increase During Deep Recession: Preliminary Data From GreeceInequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.Discounts and rebates granted to public payers for medicines in European countriesPotential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?Overview of external reference pricing systems in Europe.Novel methodology for pharmaceutical expenditure forecastValue added medicines: what value repurposed medicines might bring to society?Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.Social and economic value of Portuguese community pharmacies in health care.Policy challenges and reforms in small EU member state health systems: a narrative literature review.Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction.The effect of the late 2000s financial crisis on suicides in Spain: an interrupted time-series analysis.Cost analysis for the implementation of a medication review with follow-up service in Spain.Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.Price comparison of high-cost originator medicines in European countries.Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.Drug pricing and reimbursement information management: processes and decision making in the global economy.Drug tendering: drug supply and shortage implications for the uptake of biosimilarsHealth protection in times of economic crisis: challenges and opportunities for Europe.Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability.Policies beyond the crisis: lesson learned.The influence of a sustained multifaceted approach to improve antibiotic prescribing in Slovenia during the past decade: findings and implications.Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications.The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review
P2860
Q28540727-B5EDD4EE-B3FA-4A7F-9258-D9785B9D208AQ33730376-F130C382-598A-433B-A31A-CEC73817C284Q33816182-F76C0E32-F396-469E-8D95-20F4D7A9D6D1Q34020812-11A5B352-BECA-4209-A288-569097C21FF2Q34399553-7CF4BB51-0543-4AEF-B236-4A82FC52E5B3Q35021173-E9478879-F940-48FD-B379-8A4D3D38CF29Q35022943-8CDF5AA1-6C07-4EE5-8FEF-2103A4D46190Q35884906-64D640E7-B0DE-46F6-BE63-C958A6BEAAD6Q35993355-43747AAA-3EE1-4C46-9495-07A833C4908FQ36006795-1DD96C22-E720-4392-B470-BF705572DC5EQ36109450-4CA51AFD-3562-4948-BADE-539F936CA279Q36231161-B914ED74-70C8-4D96-9891-DD573E317A64Q36255229-3509E324-8981-41A3-A238-D169DF06F439Q36317043-B8BB8F96-72C8-419B-A65B-6B60B141B46AQ36512458-D8A945EA-7BCA-41FF-9DD1-625E7A90BC6FQ36564950-676CC7FA-7634-4EBA-84C3-49F723DC860DQ36714690-CCD27539-2918-4497-9962-56530C805148Q36897817-358F7632-72A9-4CE3-B358-2709CAE59BC9Q37669600-E9A44116-7B3E-44B9-9179-38017755A342Q38162867-D0F9231C-2EB4-49AD-B107-F4A292346C6CQ38263092-055E99C0-D238-4424-8FCD-D7602AA5E96FQ38603342-E312A2F8-5274-4911-99DA-2F6584B14B23Q38874058-8806EB04-99E6-412F-B3C3-314834233EA5Q39120116-AB932165-A56A-46CA-B4D7-040678CE3AE5Q39189020-0B250BEF-1EF9-460C-B44B-2547CB70CEF9Q39256864-57388BAE-CDA5-4619-BCC9-39A541CF9226Q39327217-B3F297BA-9027-4AD7-898D-CD796C2DAAF0Q39362176-A6EB0B02-7008-4E15-99DF-462172B682D0Q39455869-5D9ED1C4-CBD0-47A5-B206-ED97FB2B696DQ41002169-6B39A7BA-4BB7-48BA-B8DF-221462E675D9Q42370596-781E3316-A726-4A7A-8CEF-28394487442CQ43869884-4E85CFDA-8AA5-4699-B490-D130F997E5BDQ45349937-AACBFB5D-AA29-4BEE-A4F6-EA894A9CFCC2Q49182087-4A2AB658-2176-4772-BAE1-77BC637E967FQ50602640-DDC307E1-4CAC-4513-847A-BB8C77AF1147Q51202982-16B87D36-568A-4371-86AA-5F28215BD3AFQ57134241-A07AB15A-52A6-43AF-B64B-FBF6FB22C11C
P2860
Pharmaceutical policies in European countries in response to the global financial crisis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmaceutical policies in European countries in response to the global financial crisis.
@ast
Pharmaceutical policies in European countries in response to the global financial crisis.
@en
Pharmaceutical policies in European countries in response to the global financial crisis.
@nl
type
label
Pharmaceutical policies in European countries in response to the global financial crisis.
@ast
Pharmaceutical policies in European countries in response to the global financial crisis.
@en
Pharmaceutical policies in European countries in response to the global financial crisis.
@nl
prefLabel
Pharmaceutical policies in European countries in response to the global financial crisis.
@ast
Pharmaceutical policies in European countries in response to the global financial crisis.
@en
Pharmaceutical policies in European countries in response to the global financial crisis.
@nl
P2093
P2860
P356
P1433
P1476
Pharmaceutical policies in European countries in response to the global financial crisis
@en
P2093
Kees de Joncheere
Nina Zimmermann
Sabine Vogler
P2860
P356
10.5655/SMR.V4I2.1004
P577
2011-12-02T00:00:00Z